Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
02:02pm, Wednesday, 29'th Oct 2025
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, wit
Global Partners Declares Third-Quarter 2025 Cash Distribution of $0.7550 on Common Units
08:30am, Tuesday, 28'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
08:00am, Monday, 27'th Oct 2025
SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines compa
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on s
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
12:36am, Monday, 27'th Oct 2025
China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in N
Global Partners LP to Host Third-Quarter 2025 Financial Results Conference Call on November 7, 2025
08:30am, Friday, 24'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its third-quarter 2025 financial results before th
West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand
12:16pm, Thursday, 23'rd Oct 2025
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the injectable pharmaceutical packaging and delivery systems company's third-quarter 2025 earnings surpassed analyst estimate
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
04:05pm, Tuesday, 21'st Oct 2025
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participan
Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill
03:27pm, Tuesday, 21'st Oct 2025
A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives Trump credit on drug prices.
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
08:23am, Tuesday, 21'st Oct 2025
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Plan
West Pharmaceutical Services: HVP Moat Cum GLP-1 And Biologics Tailwinds Reinforce Upward Momentum
05:57am, Tuesday, 21'st Oct 2025
West Pharmaceutical Services earns a Buy rating with a $320 price target, reflecting ~18% upside with strong long-term growth prospects. WST's high-value product mix is expanding, driving margin growt
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall
Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming
09:39am, Saturday, 18'th Oct 2025
The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of i
President Trump targets $150 MFN price for GLP-1s
07:32pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
05:25pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th
